Benzinga | Sep 9, 2021 06:51AM EDT

Stifel Upgrades Biomarin Pharmaceutical to Buy, Raises Price Target to $96

Stifel analyst Paul Matteis upgrades Biomarin Pharmaceutical (NASDAQ:BMRN) from Hold to Buy and raises the price target from $86 to $96.